Treatment of Metastatic Tumors of the Urogenital Area With Cytokine-induced Killer Cells

Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus

Status and phase: Unknown; Phase 2; Phase 1

Conditions: Bladder Cancer; Renal Cancer

Treatments: Biological: cytokine-induced killer cells; Other: Standard treatment according to the Clinical protocols

Study type: Interventional

Funder types: Other

Identifiers

NCT05108077

IBCE_CIK

Details and patient eligibility

About

Treatment of metastatic tumors of the urogenital area with cytokine-induced killer cells

Full description

Treatment of metastatic tumors of the urogenital area using autologous cytokine-induced killer cells

Enrollment: 20 estimated patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Histologically confirmed diagnosis of pTa metastatic tumors of the urogenital area;
• Patient who require repetitive transurethral resection;
• Expression of muc-1/wt-1 by the tumor;
• EGOC 0-3;

Exclusion criteria

• any medical condition which can be associated with the high risk for the patient;
• pregnancy/lactation;
• chronic infections, including hepatitis B/C, tuberculosis, HIV

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

20 participants in 2 patient groups

Cytokine-induced killer cells

Experimental group

Description:

Patients with the metastatic tumors of the urogenital area receiving standard treatment and autologous cytokine-induced killer cells

Treatment:

Other: Standard treatment according to the Clinical protocols

Biological: cytokine-induced killer cells

Control

Active Comparator group

Description:

Patients with metastatic tumors of the urogenital area receiving standard treatment

Treatment:

Other: Standard treatment according to the Clinical protocols